Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Clinical trial NCT06847724 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06847724
- Sponsor
- Sandoz
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-10
- Primary completion
- 2026-11-01
- Enrollment
- 183
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.